Genomic Profiling of Stage II Colorectal Cancer Identifies Candidate Genes Associated with Recurrence-Free Survival, Tumor Location, and Differentiation Grade

Abstract

Background: Identification of high-risk stage II colorectal cancer (CRC) patients, potential candidates for adjuvant chemotherapy, is challenging. Current clinical guidelines rely mainly on histopathological markers with relatively weak prognostic value. This motivates further search for prognostic markers. Methods: This explorative study aimed to identify potential candidate gene mutations to facilitate differentiation between subgroups of patients with CRC stage II. Panel-based massive parallel sequencing was used to genetically characterize tumor tissues from 85 patients radically operated for CRC stage II, of which 12 developed recurrent cancer during follow-up. Genetic data was compared between patients with or without cancer recurrence, between tumors located in colon and in rectum, and for association with tumor differentiation grade. Results: Genetic variation in ATM, C11ORF65 was associated with recurrence-free survival. Previous reports regarding the association between BRAF mutation and a higher age at diagnosis, and tumor location in colon were confirmed. APC, BRAF, or KRAS mutation was associated with tumor differentiation grade. Multiple correspondence analyses revealed no obvious clustering of patients with the studied clinical characteristics, indicating that the genetic signatures observed here were unique for each individual. Conclusions: Taken together, we have demonstrated the utility of panel-based massive parallel sequencing to explore the pathogenesis of CRC stage II. We have identified promising candidate gene mutations associated with cancer recurrence, tumor location, and differentiation grade in patients with CRC stage II, which merit further investigation.

Association of clinical outcomes and the predictive value of T lymphocyte subsets within colorectal cancer patients

“…An increase in CD4 + T-lymphocyte content and CD4 + /CD8 + ratio means that the tumor is still in an early clinical stage, while an increase in CD8 + T-lymphocyte content means that the tumor has escalated to an advanced stage. The degree of tumor differentiation is often an important risk factor that affects the prognosis of patients ( 13 ). Our results found significant correlations of reduced CD4 + T-lymphocyte content, reduced CD4 + /CD8 + ratio, and increased CD8 + T-lymphocyte content with poorer tumor tissue differentiation.…”

Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer

“…Highly mutated APC and KRAS showed significantly different mutational frequencies between patients with dMMR_MSI-H LS and dMMR_MSI-H sporadic CRCs. They have also been reported to be highly mutated and to play key roles in CRCs 26,27 . The LS unique mutated genes included TLL1, SALL4, FAM46C, FZD2, ARID2, INPP4B, and WAS.…”